TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03730012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gilteritinib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gilteritinib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Intravenous infusion
Study: NCT03969511

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: direct angio-suite admission
Description: Upon arrival in angio-suite and after neurological examination with scoring NIHSS and mRS, and performing the blood sample, patient undergoes rotational CBCT in order to confirm ischemic stroke. Mechanical thrombectomy is the performed as well as intravenous thrombolysis when contraindications are excluded.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard management
Description: Arrival is in the MRI/CT-scan room or in the emergency department. Directly after neurological examination and blood sample, patient undergoes imaging and then bridging therapy when indicated.
Study: NCT01843595

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REFIT Intervention
Description: The intervention will include 2 face-to-face group meetings, weekly check-in sessions, weekly tailored feedback, and weekly lessons focused on specific weight loss behaviors. All participants will be encouraged increase their physical activity to approximately 250 minutes of moderate to vigorous physical activity per week.
Study: NCT00460369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sulfadoxine-pyrimethamine
Description: tablets 1,25/25 mg~1 tablet per 20 kg of body weight Single drug intake

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artemether-lumefantrine
Description: tablets 20/120 mg~* 1 tablet twice daily for 3 days below 15 kg of bodyweight~* 2 tablets twice daily for 3 days below 24 kg of bodyweight~* 3 tablets twice daily for 3 days below 35 kg of bodyweight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amodiaquine-artesunate coformulation
Description: one 25mg/67,5mg tablet, once daily for 3 days below 9 kg~one 50/135mg tablet, once daily for 3 days below 18 kg
Study: NCT01394718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Acetaminophen
Description: Scheduled doses of 15 mg/kg of IV acetaminophen will be administered to the treatment arm of the study for a total of 8 doses over a 48 hour period post-operatively.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline placebo will be given at the time of skin closure intra-operatively and will continue to receive IV saline for 44 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
Study: NCT04072575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP6M injection Dose 1
Description: Participants will receive Dose 1 PP6M intramuscular (IM) injection at Visit 1 (Day) then once every 6 month up to 24 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PP6M injection Dose 2
Description: Participants will receive Dose 2 PP6M IM injection at Visit 1 (Day) then once every 6 month up to 24 months.
Study: NCT04469426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive online informational and peer support app
Description: The app contains LARS information, bowel function diaries, and online platform with trained peer support mentor
Study: NCT00446342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNS-032 Injection
Description: Stage 1: Escalating doses of SNS-032 on days 1, 8 and 15 per 28 day cycle~Stage 2: Same as stage 1 except SNS-032 administered at the maximum tolerated dose established in stage 1
Study: NCT04537455

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultra-high frequency electrocardiography
Description: Patients will have an ultra-high frequency electrocardiography performed.
Study: NCT02609503

Intervention type: RADIATION
Group type: OTHER
Intervention: Intensity Modulated Radiation Therapy
Description: Eligible participants will receive Intensity Modulated Radiation Therapy daily x 7 weeks
Study: NCT03370835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol succinate ER
Description: Cardioselective beta-blocker

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate ER
Description: Cardioselective beta-blocker
Study: NCT01928940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib
Description: 150 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib
Description: 2 mg once daily
Study: NCT02905513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contraceptive app instant messages
Study: NCT02493387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The group-based exercise program consists of 60-minute sessions twice a week for 3 months, including central circulatory exercise performed on an ergometer cycle and muscle training, and one or two occasions of home-based exercise. The exercise program are designed after the patients requirements and with the intensity 13-17 on the Borg RPE 6-20 scale

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: The patients randomized PAP will receive a PAP prescription and a physical activity diary. The PAP and physical activity diary will be followed up at 6 and 12 weeks after the inclusion.
Study: NCT01012167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin: 24 IU in the morning and 24 IU in the evening given by nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Galantamine
Description: Galantamine: 4 mg twice a day for 1 week, then 8 mg twice a day for 1 week, then 12 mg twice a day for 4 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-Oxytocin
Description: Saline nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Oxytocin
Description: Saline nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo-Galantamine
Description: Placebo tablets twice a day for 6 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Galantamine
Description: Placebo tablets twice a day for 6 weeks
Study: NCT02905513

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mobile phone app

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile phone app
Study: NCT03063307

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atraumatic Restorative Treatment
Study: NCT02761720

Intervention type: OTHER
Intervention: No Intervention

Intervention type: OTHER
Intervention: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Study: NCT00591071

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strict glycemic control
Description: Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level below 6.1 mmol/L
Study: NCT03063307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Silver Diamine Fluoride
Study: NCT02408965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methergine
Description: 0.2 mg of methylergonovine maleate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: saline placebo to maintain blinding
Study: NCT04888455

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative sensory testing (QST)
Description: Demographic data, pain characteristics, health status, emotional well-being, personality and lifestyle are assessed by questionnaires. Additionally, all patients underwent a clinical neurological examination and quantitative sensory testing (QST) according to the German Research Network on Neuropathic Pain (DFNS).

Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative sensory testing (QST)
Description: Demographic data, pain characteristics, health status, emotional well-being, personality and lifestyle are assessed by questionnaires. Additionally, all patients underwent a clinical neurological examination and quantitative sensory testing (QST) according to the German Research Network on Neuropathic Pain (DFNS).
Study: NCT03214887

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV-P1501
Description: Gel-like product with BMMNCs in each ml of hyaluronan (HA) solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV-P1501
Description: Gel-like product with BMMNCs in each ml of hyaluronan (HA) solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV-P1501
Description: Gel-like product with BMMNCs in each ml of hyaluronan (HA) solution
Study: NCT03946202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen Peroxide
Description: Hydrogen Peroxide
Study: NCT04180215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB-201 intravenous administration.
Description: Dose / Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB-202 intravenous administration alternating with HB-201 intravenous administration.
Description: Dose / Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB-201 intravenous administration + standard of care regimen including pembrolizumab.
Description: Dose Expansion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB-202 / HB-201 alternating intravenous administration + pembrolizumab.
Description: Dose Expansion
Study: NCT00591071

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional glycemic control
Description: Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level at 11 mmol/L
Study: NCT02340780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Study: NCT04070222

Intervention type: OTHER
Intervention: Hysteroscopy
Description: 1. Three groups of patients will be enrolled: Natural labour group, Cesarean scar group and Cesarean with diverticulum (PCSD) group;~2. Hysteroscopy will be carried out for uterine cavity examine and the specimen collection for further microflora analysis and inflammation marker detection;~3. ART will be carried out with standard protocol and the clinical outcome will be recorded;~4. The primary outcome of the study is the comparation of species and communities of uterine microflora and inflammatory markers of the female uterus among three groups. The secondary outcome is biochemical pregnancy rate, clinical pregnancy rate, embryo implantation rate and live birth rate.

Intervention type: OTHER
Intervention: Hysteroscopy
Description: 1. Three groups of patients will be enrolled: Natural labour group, Cesarean scar group and Cesarean with diverticulum (PCSD) group;~2. Hysteroscopy will be carried out for uterine cavity examine and the specimen collection for further microflora analysis and inflammation marker detection;~3. ART will be carried out with standard protocol and the clinical outcome will be recorded;~4. The primary outcome of the study is the comparation of species and communities of uterine microflora and inflammatory markers of the female uterus among three groups. The secondary outcome is biochemical pregnancy rate, clinical pregnancy rate, embryo implantation rate and live birth rate.

Intervention type: OTHER
Intervention: Hysteroscopy
Description: 1. Three groups of patients will be enrolled: Natural labour group, Cesarean scar group and Cesarean with diverticulum (PCSD) group;~2. Hysteroscopy will be carried out for uterine cavity examine and the specimen collection for further microflora analysis and inflammation marker detection;~3. ART will be carried out with standard protocol and the clinical outcome will be recorded;~4. The primary outcome of the study is the comparation of species and communities of uterine microflora and inflammatory markers of the female uterus among three groups. The secondary outcome is biochemical pregnancy rate, clinical pregnancy rate, embryo implantation rate and live birth rate.
Study: NCT04180215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab.
Description: Dose Expansion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)
Description: Dose escalation; 10 patients
Study: NCT00841971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Description: 200 mg IV loading dose followed by 100 mg qd for 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: 400 mg IV for 21 days
Study: NCT01883128

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI Targeted biopsies
Description: Image registration will be used to target biopsies followed by full mapping biopsies of the prostate. All biopsies will be carried out transperineally
Study: NCT02005653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine
Description: Diethylcarbamazine 300 mg tablet as single dose per day for 12 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine
Description: Diethylcarbamazine 300 mg tablet as single dose per day for 12 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine
Description: Diethylcarbamazine 300 mg tablet as single dose per day for 12 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diethylcarbamazine
Description: Diethylcarbamazine 300 mg tablet as single dose per day for 12 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Experimental
Study: NCT00975520

Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Patients will be observed after surgery until recurrence when they will be offered radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Patients randomised to the Investigational treatment arm, will receive adjuvant curative post-operative radiation therapy aiming to reduce the rate of local recurrence. The recommended dose prescribed is 48 Gy in 20 fractions over 4 weeks.
Study: NCT02365298

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A
Description: etafilcon A soft contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: etafilcon A soft contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nelfilcon A
Description: nelfilcon A

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nelfilcon A
Description: nelfilcon A
Study: NCT02213926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196 (acalabrutinib)
Study: NCT04196972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Receive ECHO telementoring intervention
Study: NCT05767073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle InterVEntion (LIVE)
Description: The lifestyle intervention Coaching on Lifestyle (CooL) (van Rinsum 2018)),formed the basis of LIVE and was adapted to specific dysfunctional elements in depressed patients regarding motivation and self-management.~The focus is on reducing depressive symptoms, enhancing the quality of life and possibly achieving weight loss.~The lifestyle intervention lasts six months, with 13 weekly 1.5 to 2 hour group sessions and five 45 to 60 -minute individual sessions with at least one person from the patient's support network of friends or family (preferably sharing the same household). All sessions end with individual homework exercises, and each session starts with a 10 to 15-minute positive psychology intervention (PPI) and 5 to 15 minutes of physical activity. These sessions are followed by two booster sessions after about two and six months. Groups consist of 4-8 people.
Study: NCT02729324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Radiation Protectants (FORRAD®)
Description: Medical Radiation Protectants (FORRAD®) is prescribed at the beginning of radiotherapy for free. Patients are asked to start topical application of Medical Radiation Protectants (FORRAD®) on irradiated skin at the onset of radiotherapy, three times a day (30 minutes before radiotherapy, after radiotherapy, and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation dermatitis. When grade 2 or higher radiation dermatitis is developed, patients can continue using Medical Radiation Protectants (FORRAD®). When grade 3 or higher radiation dermatitis happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted, until moist desquamation is cured.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trolamine (Biafine)
Description: Trolamine (Biafine) is prescribed at the beginning of radiotherapy. Patients are asked to start topical application of trolamine (Biafine) on irradiated skin at the onset of radiotherapy, three times a day, until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation dermatitis. No other prophylactic creams, lotions, or gels are allowed. When grade 2 or higher radiation dermatitis is developed, patients cannot use trolamine any more, and they will receive other conventional medical care for treatment of radiation dermatitis in the investigators institution. When grade 3 or higher radiation dermatitis happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted, until moist desquamation is cured.
Study: NCT00980278

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus lift augmentation and dental implant
Description: transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aastrom BRCs
Description: sinus augmentation, BRC application, dental implant
Study: NCT00846781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denufosol tetrasodium Inhalation Solution
Description: 60 mg by oral inhalation three times daily
Study: NCT01121874

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ligament reconstruction with suture fixation system
Description: CMC arthroplasty consisting of reconstruction of the palmar oblique ligament using a suture fixation system

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ligament Reconstruction with Tendon Interposition (LRTI)
Description: commonly performed CMC arthroplasty technique, consisting of a trapeziectomy, followed by palmar oblique ligament reconstruction using a harvested flexor tendon from the wrist.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ligament reconstruction with suture fixation system
Description: CMC arthroplasty consisting of reconstruction of the palmar oblique ligament using a suture fixation system, with a decreased period of immobilization from 6 weeks to 2 weeks.
Study: NCT02463162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conversations Matter videos
Description: 2 videos about Advance Care Planning and Goals of Care Designations respectively. These 2 videos were developed by Alberta Health Services and are each 8 minutes long.
Study: NCT03127345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: Intravenous omega 3 fatty acid administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid
Description: Standard of care
Study: NCT00478556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omnipaque
Description: Oral CT contrast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gastroview
Description: Oral CT contrast
Study: NCT01716832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Walking
Description: Mindful walking in a small group twice a week for 60 minutes within 4 weeks.
Study: NCT01941316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 20/36 \* mg/m\^2 stepped up dosing, IV infusion (over 30 min), on days 1, 2, 8, 9, 15 and 16 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 20/36 \* mg/m\^2 stepped up dosing, IV infusion (over 30 min), on days 1, 2, 8, 9, 15 and 16 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 20/36 \* mg/m\^2 stepped up dosing, IV infusion (over 30 min), on days 1, 2, 8, 9, 15 and 16 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 20/36 \* mg/m\^2 stepped up dosing, IV infusion (over 30 min), on days 1, 2, 8, 9, 15 and 16 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 125 mg/m\^2, IV infusion (over 90 min), on days 1, 8, 15 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 125 mg/m\^2, IV infusion (over 90 min), on days 1, 8, 15 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 125 mg/m\^2, IV infusion (over 90 min), on days 1, 8, 15 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 125 mg/m\^2, IV infusion (over 90 min), on days 1, 8, 15 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.